 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 March 1995 | Volume 122 Issue 6 | Pages 430-433
Objective: To examine the relation between postmenopausal hormone use and development of systemic lupus erythematosus.
Design: Prospective cohort study.
Setting: Nurses' Health Study.
Patients: 69 435 women aged 30 to 55 years in 1976 who reported that they had completed menopause and did not have systemic lupus erythematosus or any connective tissue disease were followed every 2 years from 1976 to 1990. These women were classified as never-or ever-(current and past) users of postmenopausal hormones.
Measurements: Incidence rates of systemic lupus erythematosus and classification criteria from the American College of Rheumatology that were confirmed by chart review.
Results: With never-users of postmenopausal hormones as the reference group, age-adjusted relative risks for systemic lupus erythematosus (n = 45 women) were 2.1 (95% CI, 1.1 to 4.0) for ever-users, 2.5 (CI, 1.2 to 5.0) for current users, and 1.8 (CI, 0.8 to 4.1) for past users. A proportional increase in the risk for systemic lupus erythematosus was observed that was related to the duration of use of postmenopausal hormones (test for trend, P = 0.011).
Conclusions: Postmenopausal hormone therapy is associated with an increased risk for developing systemic lupus erythematosus.
Author and Article Information
From Harvard Medical School, Brigham and Women's Hospital, and Harvard School of Public Health, Boston, Massachusetts.
BRIEF COMMUNICATION
Postmenopausal Estrogen Therapy and the Risk for Developing Systemic Lupus Erythematosus
Requests for Reprints: Graham A. Colditz, MBBS, Nurses' Health Study, Channing Laboratory, 180 Longwood Avenue, Boston, MA 02115.
Acknowledgments: The authors thank the nurses who participated in this study; Karen Corsano, Barbara Egan, and Mark Shneyder for their expert assistance; and F.E. Speizer, the principal investigator of the Nurses' Health Study, for providing access to the database and suggestions.
Grant Support: By NIH grants CA 40396 and AR36308. Dr. Sanchez-Guerrero is supported by a Research Fellowship Award, Fogarty International Center, NIH 5F05 TW04573-02.
This article has been cited by other articles:
|
|
 |
|
  J. Cohen-Solal, V Jeganathan, L Hill, D Kawabata, D Pinto-Rodriguez, C Grimaldi, and B Diamond Hormonal regulation of B-cell function and systemic lupus erythematosus Lupus, June 1, 2008; 17(6): 528 - 532. [Abstract] [PDF]
|
|
|
|
|
|
S Koskenmies, T. Jarvinen, P Onkamo, J Panelius, U Tuovinen, T Hasan, A Ranki, and U Saarialho-Kere Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations Lupus, April 1, 2008; 17(4): 337 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 R. H. Straub The Complex Role of Estrogens in Inflammation Endocr. Rev., August 1, 2007; 28(5): 521 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G Carroll and L. E Cavanagh Drug-Induced Lupus Associated with Synthetic Conjugated Estrogens Ann. Pharmacother., April 1, 2007; 41(4): 702 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Fernandez, G McGwin Jr, A M Bertoli, J Calvo-Alen, G S Alarcon, and LUMINA Study Group Letter to the Editor Lupus, September 1, 2006; 15(9): 621 - 622. [PDF]
|
|
|
|
 |
|
 J. Sanchez-Guerrero, A. G. Uribe, L. Jimenez-Santana, M. Mestanza-Peralta, P. Lara-Reyes, A. H. Seuc, and M.-d.-C. Cravioto A Trial of Contraceptive Methods in Women with Systemic Lupus Erythematosus N. Engl. J. Med., December 15, 2005; 353(24): 2539 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Cutolo, A Sulli, and B Seriolo Estrogens, autoimmunity and the heart Lupus, September 1, 2005; 14(9): 675 - 678. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Buyon, M. A. Petri, M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, J. T. Merrill, L. Sammaritano, M. Lockshin, G. S. Alarcon, et al. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial Ann Intern Med, June 21, 2005; 142(12_Part_1): 953 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y J Lee, K S Shin, S W Kang, C K Lee, B Yoo, H S Cha, E M Koh, S J Yoon, and J Lee Association of the oestrogen receptor {alpha} gene polymorphisms with disease onset in systemic lupus erythematosus Ann Rheum Dis, October 1, 2004; 63(10): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-b. Liu, K. K. Loo, K. Palaszynski, J. Ashouri, D. B. Lubahn, and R. R. Voskuhl Estrogen Receptor {alpha} Mediates Estrogen's Immune Protection in Autoimmune Disease J. Immunol., December 15, 2003; 171(12): 6936 - 6940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C C Mok and C S Lau Pathogenesis of systemic lupus erythematosus J. Clin. Pathol., July 1, 2003; 56(7): 481 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Humphries and S. Gill Risks and benefits of hormone replacement therapy: The evidence speaks Can. Med. Assoc. J., April 15, 2003; 168(8): 1001 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J P. Vilar and E I Sato Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil) Lupus, August 1, 2002; 11(8): 528 - 532. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. CID, H. W. SCHNAPER, and H. K. KLEINMAN Estrogens and the Vascular Endothelium Ann. N.Y. Acad. Sci., June 1, 2002; 966(1): 143 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Bengtsson, L. Rylander, L. Hagmar, O. Nived, and G. Sturfelt Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden Rheumatology, May 1, 2002; 41(5): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T E McAlindon, J Gulin, T Chen, T Klug, R Lahita, and M Nuite Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity Lupus, November 1, 2001; 10(11): 779 - 783. [PDF]
|
|
|
|
|
|
M Petri Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy Lupus, March 1, 2001; 10(3): 222 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Hernan, M. J. Hohol, M. J. Olek, D. Spiegelman, and A. Ascherio Oral contraceptives and the incidence of multiple sclerosis Neurology, September 26, 2000; 55(6): 848 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Blumenfeld, D Shapiro, M Shteinberg, I Avivi, and M Nahir Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy Lupus, July 1, 2000; 9(6): 401 - 405. [Abstract] [PDF]
|
|
|
|
|
|
R. L. WILDER and I. J. ELENKOV Hormonal Regulation of Tumor Necrosis Factor-{alpha}, Interleukin-12 and Interleukin-10 Production by Activated Macrophages: A Disease-modifying Mechanism in Rheumatoid Arthritis and Systemic Lupus Erythematosus? Ann. N.Y. Acad. Sci., June 22, 1999; 876(1): 14 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Tebbe and C. Orfanos Epidemiology and socioeconomic impact of skin disease in lupus erythematosus Lupus, January 1, 1997; 6(2): 96 - 104. [Abstract] [PDF]
|
|
|
|
|
|
M. Lockshin Occasional Series Why women? Lupus, January 1, 1997; 6(8): 625 - 632. [PDF]
|
|
|
|
|
|
J. P. Buyon, H. M. Belmont, and K. C. Kalunian Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus Ann Intern Med, December 15, 1995; 123(12): 961 - 961. [Full Text]
|
|
|
|
|
|
J.-C. Piette, L. T. H. Du, and T. Papo Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus Ann Intern Med, December 15, 1995; 123(12): 961 - 962. [Full Text]
|
|
|
|
|
|
M.H. Liang and E.W. Karlson Prevalence of SLE: Higher or lower ? Lupus, December 1, 1995; 4(6): 421 - 422. [PDF]
|
|
Article
